- Home
- CYH vs CELC Comparison
CYH vs CELC Comparison
Compare CYH & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- CELC
- Stock Information
- Founded
- CYH 1985
- CELC 2011
- Country
- CYH United States
- CELC United States
- Employees
- CYH N/A
- CELC N/A
- Industry
- CYH Hospital/Nursing Management
- CELC Medical Specialities
- Sector
- CYH Health Care
- CELC Health Care
- Exchange
- CYH Nasdaq
- CELC Nasdaq
- Market Cap
- CYH 373.7M
- CELC 391.0M
- IPO Year
- CYH 1991
- CELC 2017
- Fundamental
- Price
- CYH $2.71
- CELC $10.11
- Analyst Decision
- CYH Hold
- CELC Strong Buy
- Analyst Count
- CYH 7
- CELC 6
- Target Price
- CYH $4.10
- CELC $30.17
- AVG Volume (30 Days)
- CYH 2.0M
- CELC 248.4K
- Earning Date
- CYH 04-23-2025
- CELC 03-31-2025
- Dividend Yield
- CYH N/A
- CELC N/A
- EPS Growth
- CYH N/A
- CELC N/A
- EPS
- CYH N/A
- CELC N/A
- Revenue
- CYH $12,634,000,000.00
- CELC N/A
- Revenue This Year
- CYH N/A
- CELC $49.98
- Revenue Next Year
- CYH $4.08
- CELC N/A
- P/E Ratio
- CYH N/A
- CELC N/A
- Revenue Growth
- CYH 1.15
- CELC N/A
- 52 Week Low
- CYH $2.53
- CELC $8.53
- 52 Week High
- CYH $6.29
- CELC $22.04
- Technical
- Relative Strength Index (RSI)
- CYH 41.52
- CELC 43.41
- Support Level
- CYH $2.72
- CELC $9.98
- Resistance Level
- CYH $2.85
- CELC $10.70
- Average True Range (ATR)
- CYH 0.13
- CELC 0.68
- MACD
- CYH 0.02
- CELC 0.06
- Stochastic Oscillator
- CYH 48.53
- CELC 28.38
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.